Stocks to Watch : Jacobs Solutions, Argenx

Published: 2025-04-10 17:44:00 ET J

By Connor Hart

Jacobs Solutions disclosed post-closing adjustments stemming from a transaction it completed with Amentum last year. The Dallas company received $70 million and the right to receive nearly 7.3 million shares of Amentum's common stock. Jacobs used the money to repay a portion of debt and plans to distribute Amentum's stock to its shareholders. Shares up 6.9%, to $122.80, in after-hours trading.

Argenx received approval from the Food and Drug Administration for a new delivery method of its treatment for certain patients with a rare autoimmune disease. The approval of the treatment, Vyvgart Hytrulo, in a prefilled syringe for self-injection is supported by data from studies evaluating its bioequivalence to the treatment in a vial, the immunology company said. The prefilled syringe is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver or healthcare professional. American depositary receipts rise 6.2%, to $580, in post-market trading.

Write to Connor Hart at [email protected]

(END) Dow Jones Newswires

04-10-25 1944ET